Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
Clinical trial NCT02319031 · COMPLETED
Trial details
- NCT number
- NCT02319031
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-01
- Primary completion
- 2015-10-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.